Allison C. Hoffman Sells 8,426 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 8,426 shares of Phreesia stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $27.31, for a total value of $230,114.06. Following the sale, the general counsel now directly owns 146,126 shares of the company’s stock, valued at $3,990,701.06. This represents a 5.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Phreesia Trading Down 0.2 %

NYSE:PHR traded down $0.06 during midday trading on Wednesday, reaching $27.29. 389,445 shares of the stock traded hands, compared to its average volume of 386,096. The stock has a market capitalization of $1.59 billion, a P/E ratio of -18.56 and a beta of 0.94. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74. The company has a fifty day moving average of $23.77 and a 200 day moving average of $22.94. Phreesia, Inc. has a 12 month low of $17.07 and a 12 month high of $29.16.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. During the same period in the prior year, the business posted ($0.58) earnings per share. Phreesia’s revenue for the quarter was up 16.6% on a year-over-year basis. On average, research analysts predict that Phreesia, Inc. will post -1.1 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $24.00 to $32.00 in a research report on Wednesday, January 8th. Robert W. Baird lowered their price target on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Truist Financial increased their price objective on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research report on Friday, January 10th. Finally, JMP Securities reiterated a “market outperform” rating and set a $30.00 price target on shares of Phreesia in a research report on Tuesday, December 10th. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia has a consensus rating of “Buy” and a consensus target price of $31.00.

Hedge Funds Weigh In On Phreesia

Several hedge funds have recently made changes to their positions in PHR. Hsbc Holdings PLC bought a new position in Phreesia in the second quarter worth about $301,000. Sei Investments Co. grew its holdings in shares of Phreesia by 135.3% during the 2nd quarter. Sei Investments Co. now owns 165,327 shares of the company’s stock worth $3,505,000 after acquiring an additional 95,058 shares during the period. Ensign Peak Advisors Inc raised its position in shares of Phreesia by 3.2% in the 2nd quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after acquiring an additional 700 shares in the last quarter. Lombard Odier Asset Management USA Corp purchased a new position in shares of Phreesia in the 2nd quarter valued at approximately $202,000. Finally, Point72 DIFC Ltd bought a new stake in shares of Phreesia during the second quarter valued at approximately $209,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.